Physician profile
Mohammad Ahmad
NPI 1831273036
$3,133.35
in general payments reported to CMS, 2019-2025
23 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,241 · 2020: $142 · 2021: $282 · 2022: $788 · 2023: $396 · 2024: $142 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $534.07 |
| Education | $146.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $565.22 | 2019-2022 | |
| Abbvie INC. | $549.12 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $290.02 | 2019-2023 | Rexulti |
| Lundbeck LLC | $264.80 | 2019-2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $236.56 | 2019 | |
| Neos Therapeutics, LP | $181.67 | 2019-2023 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Abbott Laboratories | $144.35 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $142.35 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $111.66 | 2019-2025 | |
| Alkermes, INC. | $109.58 | 2019-2025 | Aristada, Lybalvi |
| Allergan, INC. | $76.85 | 2019-2020 | |
| Shire North American Group INC | $76.62 | 2019 | |
| Ironshore Pharmaceuticals INC. | $75.33 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.42 | 2023 | |
| Corium, LLC | $51.23 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $46.64 | 2021 | |
| Tris Pharma INC | $33.21 | 2022-2023 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $31.18 | 2019 | |
| Aytu Biopharma, INC. | $22.02 | 2021 | |
| Noven Therapeutics, LLC | $19.83 | 2021 | |
| Jazz Pharmaceuticals INC. | $17.23 | 2022 | |
| Neurocrine Biosciences, INC. | $13.48 | 2019 | |
| Vertical Pharmaceuticals, LLC | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.